AzurRx BioPharma (AZRX) Given a $6.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $6.00 price target on AzurRx BioPharma (NASDAQ:AZRX) in a report released on Wednesday. The firm currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on the stock. HC Wainwright set a $8.00 price objective on shares of AzurRx BioPharma and gave the stock a buy rating in a research report on Friday, November 2nd. ValuEngine upgraded shares of AzurRx BioPharma from a hold rating to a buy rating in a research report on Thursday, November 1st. Finally, CIBC assumed coverage on shares of AzurRx BioPharma in a research report on Wednesday, October 17th. They issued an outperform rating and a $6.00 price objective on the stock.

AZRX stock opened at $1.76 on Wednesday. AzurRx BioPharma has a 1-year low of $1.69 and a 1-year high of $4.08.

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc increased its position in shares of AzurRx BioPharma by 2.1% in the third quarter. Vanguard Group Inc now owns 413,439 shares of the company’s stock worth $1,063,000 after purchasing an additional 8,489 shares during the last quarter. Ardsley Advisory Partners grew its position in AzurRx BioPharma by 66.3% during the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after acquiring an additional 54,697 shares during the last quarter. Opaleye Management Inc. bought a new position in AzurRx BioPharma during the second quarter valued at approximately $417,000. Finally, 683 Capital Management LLC bought a new position in AzurRx BioPharma during the second quarter valued at approximately $1,284,000. Institutional investors own 18.93% of the company’s stock.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

See Also: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply